Director · Keros Therapeutics, Inc. · Common Stock
Side
SELL
Value
$5,522
Shares
550
Price
$10.04
Executed
Jun 11, 2026
Disclosed
Jun 15, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 11 executedJun 15, 2026 disclosed
KROS · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Newton Charles W. filed this Form 4 reporting a open-market sale of KROS on Jun 11, 2026. It became public on Jun 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Newton Charles W.cik:0001866219
Issuer
Keros Therapeutics, Inc.cik:0001664710
Revision history · 0
No field has changed since this record was first ingested.
